Cortex Gets Funding for Alzheimer’s Drug Test
- Share via
Cortex Pharmaceuticals Inc., an Irvine neuroscience company, said the Institute for the Study of Aging will fund testing of the company’s Ampakine CX516 in patients with mild cognitive impairment, the earliest recognized stages of Alzheimer’s disease.
The nonprofit foundation, based in New York, will provide $247,300 as a program-related investment, which means the company must repay the amount should the drug enter phase III clinical trials. It is now in early clinical trial.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
